Update: Trading update shows momentum maintained
Skyepharma’s Q215 trading update shows progress is continuing as expected. flutiform is growing in-market sales as forecast, with further roll-outs into new, albeit smaller, markets. Royalties from the other key drivers are also on track, with rising contributions from the GSK Ellipta inhaled products, as well as solid Solaraze sales in the US. Pacira’s Exparel is still expected to trigger the $8m sales milestone this year. Our valuation, currently still based on a DCF model, is £354m or 338p a share.Skyland Petroleum is engaged in the licensing of copyright for feature films.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.